New Addition to Parkinson Therapy

• Autores: Rebecca Voelker
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 317, Nº. 17, 2017, págs. 1716-1716
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Safinamide has received FDA approval as an add-on treatment for patients with Parkinson disease who take levodopa and carbidopa but have “off” episodes, when medication doesn’t adequately control symptoms such as tremor.

    More than 1 million people in North America have Parkinson disease; about 60 000 new cases are diagnosed in the United States each year. “Parkinson’s is a relentless disease without a cure,” Eric Bastings, MD, deputy director of the FDA’s Division of Neurology Products, said in a statement.